Yahoo · Sep 15, 2026
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.
NYSE · JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$267.20
Up+$0.88 (+0.33%)
Updated Sep 16, 2026, 10:55 AM
SID Score
7.8/10
Composite research score
Smart Money
50/100
Neutral
- Market cap
- 505.78B
- P/E ratio
- 20.3
- Dividend yield
- 1.92%
- 52-week range
- $200.91 – $281.07
- Volume
- 5.28M
- Avg. volume
- 8.82M
Price performance
JNJ price history
1M range · 20 trading sessions · Daily adjusted prices
JNJ closed at $267.20 after 20 trading sessions, down 1.44% for the selected period.
- Last close
- $267.20
- Period change
- -1.44%
- Period low
- $265.58
- Period high
- $278.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $265.81 | $267.20 | $260.68 | $267.20 | 5.28M |
| Sep 14, 2026 | $271.00 | $271.55 | $266.19 | $266.32 | 4.74M |
| Sep 11, 2026 | $268.03 | $270.40 | $265.25 | $265.58 | 4.71M |
| Sep 10, 2026 | $270.21 | $271.27 | $265.72 | $266.35 | 4.93M |
| Sep 9, 2026 | $268.51 | $270.10 | $266.73 | $267.08 | 6.13M |
| Sep 8, 2026 | $271.28 | $271.99 | $266.8828 | $269.12 | 8.09M |
| Sep 4, 2026 | $275.13 | $277.80 | $274.75 | $275.23 | 4.32M |
| Sep 3, 2026 | $277.32 | $278.89 | $273.155 | $278.43 | 5.94M |
| Sep 2, 2026 | $274.74 | $281.07 | $273.53 | $275.21 | 7.91M |
| Sep 1, 2026 | $270.83 | $271.91 | $267.02 | $271.19 | 6.04M |
| Aug 31, 2026 | $267.125 | $267.77 | $265.17 | $265.85 | 7.9M |
| Aug 28, 2026 | $265.78 | $268.38 | $264.27 | $268.04 | 5.77M |
| Aug 27, 2026 | $268.45 | $268.45 | $263.83 | $265.77 | 7.31M |
| Aug 26, 2026 | $271.97 | $272.905 | $269.55 | $270.00 | 7.22M |
| Aug 25, 2026 | $271.00 | $273.8021 | $270.175 | $273.14 | 4.69M |
| Aug 24, 2026 | $269.74 | $273.98 | $268.57 | $273.04 | 5.44M |
| Aug 21, 2026 | $267.83 | $272.655 | $267.00 | $270.24 | 6.19M |
| Aug 20, 2026 | $273.40 | $273.40 | $267.37 | $267.37 | 6.48M |
| Aug 19, 2026 | $272.995 | $276.47 | $270.56 | $273.41 | 7.73M |
| Aug 18, 2026 | $267.67 | $271.73 | $266.33 | $271.11 | 7.84M |
Latest JNJ news
The latest Smart Investors Daily articles mentioning JNJ.
Stock researchCompany · Overview
JNJ research
Overview
Company profile and research snapshot.
Company profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $207.08
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Sep 2, 2026 | UBS | Buy | — |
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 3, 2026 | Wells Fargo | Overweight | — |
| Jul 17, 2026 | Guggenheim | Buy | — |
News briefing
Generated Sep 15, 2026, 9:17 PM
Why Is JNJ Up Today? Mixed Clinical Results Offset by Defensive Appeal
Johnson & Johnson edged higher by $0.33% today as investors digested a mixed bag of pharmaceutical developments and strategic positioning. The modest gain reflects the market's balancing act between setbacks in early-stage partnerships and JNJ's continued appeal as a defensive healthcare holding amid broader market uncertainty.
Bottom line: JNJ's modest upside reflects its role as a defensive healthcare stalwart rather than compelling new catalyst-driven momentum. While positive oncology data and strategic M&A positioning provide growth hooks, investors should monitor the STELARA biosimilar impact, partnership execution risks, and whether the company can sustain double-digit growth as patent cliffs approach.
Yahoo · Sep 15, 2026
Has BSX Stock Finally Hit Bottom?
Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.
Yahoo · Sep 15, 2026
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J
Yahoo · Sep 15, 2026
Apollo and J&J Face a High-Stakes Orthopedics Deal
Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction […]
AI research layers
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson Stock Performance
Johnson & Johnson shares traded at $267.20, reflecting a modest daily decline of 0.38%, per SID market data. Over the trailing twelve months, JNJ has delivered a gain of 28.94%, significantly outpacing its typically defensive profile indicated by a beta of just 0.349. On a three-month basis, the stock has appreciated 10.57%, while the one-month return stands at a more moderate 1.62%. Technically, JNJ trades above both key moving averages, with the 50-day moving average at $262.77 and the 200-day moving average at $242.94, according to Massive/Polygon data. The current price sits approximately 1.7% above the 50-day level and 10.0% above the 200-day level, confirming a sustained uptrend. However, the 14-day RSI reads 41.2, suggesting recent momentum has cooled and the stock is approaching oversold territory. Average daily volume is approximately 8.82 million shares, supporting consistent institutional liquidity.
Johnson & Johnson Valuation Analysis
Johnson & Johnson carries a market capitalization of approximately $505.8 billion, making it one of the largest companies in the Healthcare sector, per SID market data. The stock's trailing price-to-earnings ratio stands at 20.30, which reflects a moderate premium relative to historical healthcare sector averages. The PEG ratio of 1.91 suggests the stock is priced slightly above fair value when adjusting for expected earnings growth, according to SEC filings and consensus estimates. JNJ's price-to-book ratio of 6.43 indicates investors are paying a significant premium over tangible asset value, consistent with the company's strong brand portfolio and intellectual property base. The current dividend yield of 2.45% continues to position JNJ as an income-generating holding within diversified portfolios. Overall, valuation metrics reflect a company trading at a premium that accounts for its defensive characteristics, consistent dividend history, and established market position within the global healthcare industry.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score registers at 49 out of 100, generating a neutral signal per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating that large fund managers maintain strong conviction in JNJ's long-term positioning. In contrast, the insider trading component scores just 4.6 out of 25, reflecting a notable imbalance in recent executive transactions. According to SEC Form 4 filings, there have been 14 insider trades over the past 90 days, comprising 4 purchases and 10 sales. This selling activity from corporate insiders, while not uncommon for large-cap executives managing diversified personal portfolios, contributes to the subdued insider score. Dark pool activity scores 9.4 out of 25, suggesting below-average institutional block trading interest at current price levels. Congressional trading activity registers at 10.4 out of 25, per 13F institutional filings, indicating moderate legislative portfolio exposure. The divergence between strong institutional holdings and elevated insider selling creates a mixed signal for investors monitoring smart money flows.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated steady earnings execution across recent quarters, per company earnings reports. In the most recent reported quarter ending January 2026, JNJ posted earnings per share of $2.46 against a consensus estimate of $2.47, resulting in a marginal miss of $0.01. The subsequent quarter saw improvement, with actual EPS of $2.70 versus estimates of $2.67, representing a positive surprise of $0.03. The July 2026 quarter continued the upward trajectory, delivering EPS of $2.90 against analyst expectations of $2.85, a beat of $0.05. This sequential improvement from a slight miss to consecutive beats indicates strengthening operational performance. Looking ahead, the next earnings report is scheduled for October 13, 2026, with the current consensus estimate set at $2.53 per share, according to analyst estimates. The progression in quarterly results reflects improving execution across JNJ's pharmaceutical and medical technology segments.
Wall Street Analyst Ratings for JNJ
Wall Street consensus on Johnson & Johnson remains firmly positive, with recent analyst activity uniformly reaffirming bullish ratings, per Wall Street analyst reports. On September 10, 2026, HSBC reiterated its Buy rating on JNJ, followed by UBS maintaining its Buy rating on September 2, 2026. Guggenheim also reaffirmed its Buy recommendation on August 6, 2026, having previously reiterated the same call on July 17, 2026, according to SID consensus data. Wells Fargo maintained its Overweight rating on August 3, 2026. Notably, none of the five most recent analyst actions involved a downgrade or rating reduction, and no firm shifted to a neutral or sell-equivalent position. This unanimity across major global and domestic brokerages — including HSBC, UBS, Guggenheim, and Wells Fargo — reflects broad institutional confidence in JNJ's fundamental trajectory. The absence of any rating downgrades over the recent period signals that analysts view the stock's 28.94% trailing twelve-month appreciation as fundamentally supported rather than overextended.
